WASHINGTON: The growing popularity of the weight-loss drug Vigovi or Ompac has raised concerns about potential side effects, but a recent study has dismissed it.
A new study has debunked public fears about popular weight-loss drugs. Researchers have found that using these drugs does not increase a person’s risk of depression or suicide.
In an analysis of data from clinical trials, experts found that semaglutide drugs did not increase the risk of depression, suicidal thoughts, or suicidal behaviors in people without a mental health disorder.
The new study reviewed data from more than 3,500 people in four large clinical trials for semaglutide. The trials were funded by Ozampic and Novo Nordisk, which makes the Vigovi drug.
